期刊文献+

风湿性心房颤动患者左心房组织中钙蛋白酶-2的表达 被引量:4

Expression of calpain-2 in human left atrium in rheumatic atrial fibrillation
原文传递
导出
摘要 目的观察风湿性心房颤动(AF)患者左心房中钙蛋白酶-2(calpain-2)的表达,探讨其在AF发病机制中的作用。方法选取外科换瓣手术的风湿性心脏病患者39例,分为窦性心律组(n=16例)和心房颤动组(n=23例)。应用RT-PCR技术和免疫组化LSAB法半定量检测calpain-2的表达。结果心房颤动组calpain-2 mRNA的deltaCt值高于窦性心律组[(0.091±0.035)vs(0.066±0.022),P=0.017];两组左心房心肌细胞中均有棕黄色颗粒沉着,心外膜和心内膜细胞均未见棕黄色颗粒;心房颤动组中calpain-2表达含量明显高于窦性心律组(P<0.001),两者平均光密度值分别为0.92±0.17和0.65±0.01;calpain-2的含量与左心房收缩末期直径呈正相关(r=0.929,P<0.001)。结论 calpain-2在人类左心房心肌细胞中表达;AF时calpain-2的表达明显增加。 Objective To observe the expression of calpain-2 in the left atrum of patients with rheumatic atrial fibrilla-tion, and to explore its roles in the pathogenesis of atrial fibrillation.Methods A total of 39 patients with rheumatic heart disease who received surgical valve replacement were divided into two groups: the atrial fibrillation group ( n=23) and sinus rhythm group (n=16).The expression of calpain-2 was detected with LSAB immunohistochemical and the Real-time PCR technology.Results The deltaCt of calpain-2 mRNA of the atrial fibrillation group ( 0.091 ± 0.035) was higher than that of the sinus rhythm group (0.066 ±0.022, P=0.017).Brown particle deposits were ob-served in the left atrial myocytes in both groups, but the epicardial and endocardial cells showed no brown particles.The average optical density values of calpain-2 of the atrial fibrillation group and sinus rhythm group were (0.92 ±0.17) and (0.65 ±0.01)(P&lt;0.001).Calpain-2 levels and left atrial systolic diameter were correlated (r=0.929, P&lt;0.01).Conclusion Calpain-2 exists in the left atrial myocytes.The expression of calpain-2 increases significantly in case of atrial fibrillation.
出处 《山东大学学报(医学版)》 CAS 北大核心 2014年第4期93-96,共4页 Journal of Shandong University:Health Sciences
基金 山东省医药卫生科技发展计划(2011HZ073) 山东省医药卫生科技发展计划(2011BJZD05) 济南市科技计划(201202052) 山东省自然科学基金(ZR2011HM072)
关键词 心房颤动 钙蛋白酶-2 半胱氨酸蛋白酶 钙蛋白酶-2抑制剂 Calpain-2 Atrial fibrillation Cysteine protease Calpain inhibitor
  • 相关文献

参考文献16

  • 1Lloyd-Jones D M,Wang T J,Leip E P,et al.Lifetime risk for development of atrial fibrillation:the Framingham Heart Study [J].Circulation,2004,110(9):1042-1046.
  • 2程显峰,梁飞,张骞,朱小龙,张海洲,张涛,韩波,邹承伟.同期射频消融改良迷宫Ⅲ术+心脏神经节丛消融治疗心房颤动[J].山东大学学报(医学版),2013,51(2):53-56. 被引量:4
  • 3Davy J M,Roubille F,Tri Cung T,et al.Atrial fibrilla-tion in 2010:an increasing morbidity and mortality burden [J].Ann Cardiol Angeiol(Paris),2010,59(Suppl 1):4-13.
  • 4Zembala M,Filipiak K,Kowalski O,et al.Minimallyinvasive hybrid ablation procedure for the treatment of persistent atrial fibrillation:one year results [J].Kardiol Pol,2012,70(8):819-828.
  • 5Li Y D,Li J X,Tang B P,et al.Expression of tyrosine hydroxylase and growth-associated protein 43 in aging at-rial fibrillation patients of Xinjiang Uygur and Han nation-ality[J].Genet Mol Res,2013,12(4):5257-5266.
  • 6Kottkamp H.Human atrial fibrillation substrate:towards a specific fibrotic atrial cardiomyopathy [J].Cardiovasc Res,2013,34(35):2731-2738.
  • 7Xu G J,Gan T Y,Tang B P,et al.Alterations in the ex-pression of atrial calpains in electrical and structural re-modeling during aging and atrial fibrillation [J].Mol Med Rep,2013,8(5):1343-1352.
  • 8P(tramo B,Montiel T,Hemrndez-Espinosa D R,et al.Calpain activation induced by glucose deprivation is medi-ated by oxidative stress and contributes to neuronal dam-age[J].Int J Biochem Cell Biol,2013,45(11):2596-2604.
  • 9Xu G J,Gan T Y,Tang B P,et al.Alterations in the ex-pression of atrial calpains in electrical and structural re-modeling during aging and atrial fibrillation[J].Mol Med Rep,2013,8(5):1343-1352.
  • 10Sorimachi H,Suzuki K.The structure of calpain[J].J Biochem(Tokyo),2001,129(5):653-664.

二级参考文献29

  • 1王鸣和.心房颤动[M].临床心律失常诊疗手册.上海:上海科学技术文献出版社,2004:42-44.
  • 2Ausma J,Dispersyn GD,Duimel H,et al.Changes in ultrastructural calcium distribut in goat atria during atrial fibrillation[J].J Mol Cell Cardiol,2000,32(3):355-364.
  • 3Benjamin EJ,Levy D,Vaziri SM,et al.Independent risk factors for atrial fibrillation in a population-based cohort[J].The Framingham Heart Study,JAMA,1994,271:840-844.
  • 4Sanfilippo AJ,Abascal VM,Sheehan M,et al.Atrial enlargement as a consequence of atrial fibrillation:a prospective cardiographic study[J].Circulation,1990,82:792-797.
  • 5Vaziri SM,Larson M,Benjamin EJ,et al.Echocardiographic predictor of nontheumatic atrial fibrillation:the Framingham Heart Study[J].Circulation,1994,89:724-730.
  • 6Mattioli AV,Sansoni S,Lucchi GR,et al.Serial eveluation of left atrial diameter after cardioversion for atrial fibrillation and relation to atrial function[J].Am J Cardiol,2000,85(7):832-836.
  • 7Farcr S,Villemaire C,Nattel S.Importance of refractoriness heterogeneity in the enhanced vulnerability to atrial fibrillation induction caused by tachycardia-induced atrial electrical remodeling[J].Circulation,1998,98,2202-2209.
  • 8Lloyd-Jones D M, Wang T J, Leip E P, et al. Lifetime risk for development of atrial fibrillation: The Framing- ham Heart Study[J]. Circulation, 2004, 110(9) :1042- 1046.
  • 9Thrall G, Lane D, Carroll D, et al. Quality of life in pa- tients with atrial fibrillation: a systematic review [ J ]. Am J Med, 2006, 119(5) :448.
  • 10Rewiuk K, Wizner B, Fedyk-Lukasik M, et al. Epidemi- ology and management of coexisting heart failure and atri- al fibrillation in an outpatient setting [ J ]. Pol Arch Med Wewn, 2011, 121 ( 11 ) :392-399.

共引文献6

同被引文献26

引证文献4

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部